Fox Chase Cancer Center | Strategic Alliance Partners

In research published in Nicotine & Tobacco Research, lead author Charnita Zeigler-Johnson, PhD, MPH, Associate Director of Community Outreach and Engagement, studied the prevalence of smoking stigma among the African American/Black community.

Fox Chase Cancer Center has hired Alycia So, MD, as an assistant professor in the Division of Breast Surgery in the Department of Surgery.

Fox Chase Cancer Center’s Center for Immunology will host its 14th Annual Scientific Symposium on Friday, October 18, 2024.

Changes that occur with age in male skin fibroblasts resulted in an increase in the spread of melanoma cells, according to new research from Fox Chase.

Leah Grandi Holben, MD, joined Fox Chase Cancer Center as an assistant professor in the General Hematology/Oncology Program.

Eric Goodlev, MD, has joined Fox Chase Cancer Center as an associate Professor in the Supportive Oncology and Palliative Care Program.

An international team of researchers led by Fox Chase Cancer Center evaluated practice patterns and the management of dermatofibrosarcoma protuberans.

Michael Seidman, MD, has joined Fox Chase Cancer Center as a Professor in the Department of Hematology/Oncology.

Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, has been named a Fellow of the American Society for Cell Biology.

Sanjay S. Reddy, MD, FACS, OF Fox Chase Cancer Center, recently received the center’s 2024 Medical Staff Executive Committee Faculty Citizenship Award.

Researchers at Fox Chase Cancer Center have identified factors that could decrease incidence of prostate cancer in areas where rates are highest.

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Fox Chase Cancer Center announces Aitziber Buque Martinez, PhD, as an assistant professor in the Cancer Signaling and Microenvironment Research Program.

Fox Chase Cancer Center is pleased to announce the hiring of Michelle Pedersen, DO, as a hospitalist and Assistant Professor in the Division of Hospital Medicine within the Department of Medicine.

A study from Temple University and Fox Chase Cancer Center shows how protein phosphatases target proteins and regulate cell cycle progression.

Teh Lin, PhD, DABR, FAAPM, of Fox Chase Cancer Center, has been named a Fellow of the American Association of Physicists in Medicine.

Robert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.

Yu “Sunny” Liu, PhD, has received a grant from the NIGMS of the National Institutes of Health to study how misfolded human genome can cause disease.

Robert Uzzo, MD, details data from the IMmotion010 study on KIM-1 and how the biomarker could be used as well as future directions for investigating it in RCC.

Richard Bleicher, MD, FACS, has been named 2023-2024 University of Texas MD Anderson Cancer Center Breast Surgical Oncology Fellowship’s Annual Distinguished Commencement Visiting Professor.

J. Ryan Mark, MD, FACS, is joining Fox Chase Cancer Center as an associate professor in the Department of Urology and the Fox Chase – Temple Urologic Institute.

Jessica Bauman, MD, found that a new integrated palliative care rotation for hematology/oncology fellows improved their palliative care knowledge.

Jeffrey M. Farma, MD, FACS, has been appointed Chair of Surgery at Fox Chase Cancer Center.

Assistant professor Lucia Borriello, of Fox Chase Cancer Center, was recently elected to the Board of Directors for the Metastasis Research Society.

Temple University Hospital has received re-accreditation under the American College of Surgeons, Commission on Cancer Accreditation Program.

Fox Chase Cancer Center celebrated a gift of $10.8 million from the Estate of Concetta “Chet” Greenberg, an ardent champion of cancer research during her life.

Researchers at Fox Chase Cancer Center have documented the first case of rectal myxoid leiomyosarcoma, a rare cancer.

Maryclare Taylor, MD, presents findings that pancreatic cancer patients on single modality neoadjuvant therapy often face fragmented care.

A study from researchers at Temple University Hospital and Fox Chase Cancer Center found that adjuvant therapy may be underutilized in T2N0 rectal cancer.